Inhibitory effect of 2′-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 5, 2005, Pages 2050-2058

  Tomassini, Joanne E ^a,d   Getty, Krista ^a   Stahlhut, Mark W ^a   Shim, Sung ^a   Bhat, Balkrishen ^b   Eldrup, Anne B ^b   Prakash, Thazha P ^b   Carroll, Steven S ^a   Flores, Osvaldo ^a   MacCoss, Malcolm ^a   McMasters, Daniel R ^a   Migliaccio, Giovanni ^c   Olsen, David B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c Inst di Richerche di Biol Molec   (Italy)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYLADENOSINE; 2' O METHYLCYTIDINE; 2' O METHYLCYTIDINE 5' TRIPHOSPHATE; 2' O METHYLCYTIDINE PHOSPHATE; ANTIVIRUS AGENT; CYTIDINE PHOSPHATE; NUCLEOSIDE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CHEMICAL MODIFICATION; CORRELATION ANALYSIS; ENZYME SPECIFICITY; EVALUATION; GROWTH REGULATION; HEPATITIS C VIRUS; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REPLICON; RNA REPLICATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BLOTTING, NORTHERN; CELL SURVIVAL; CHEMISTRY, PHYSICAL; HEPACIVIRUS; MOLECULAR CONFORMATION; NUCLEASE PROTECTION ASSAYS; NUCLEOSIDES; PRODRUGS; REPLICON; RNA REPLICASE; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 20944435839     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.5.2050-2058.2005     Document Type: Article

References (41)

1. Andrews, D. M., H. M. Chaignot, B. A. Coomber, M. D. Dowle, S. L. Hind, M. R. Johnson, P. S. Jones, G. Mills, A. Patikis, T. J. Pateman, J. E. Robinson, M. J. Slater, and N. Trivedi. 2003. The design of potent, nonpeptidic inhibitors of hepatitis C protease. Eur. J. Med. Chem. 38:339-343.
2. Carroll, S. S., D. B. Olsen, P. L. Durette, B. Bhat, P. Dande, and A. B. Eldrup. December 2003. Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. WO patent 2,004,000,858.
3. Carroll, S. S., V. Sardana, Z. Yang, A. R. Jacobs, C. Mizenko, D. Hall, L. Hill, J. Zugay-Murphy, and L. C. Kuo. 2000. Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays. Biochemistry 39:8243-8249.
4. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
5. Chan, L., T. J. Reddy, M. Proulx, S. K. Das, O. Pereira, W. Wang, A. Siddiqui, C. G. Yannopoulos, C. Poisson, N. Turcotte, A. Drouin, M. H. Alaoui-Ismaili, R. Bethell, M. Hamel, L. L'Heureux, D. Bilimoria, and N. Nguyen-Ba. 2003. Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. J. Med. Chem. 46:1283-1285.
6. Crippen, G. M., and T. F. Havel. 1988. Distance geometry and molecular conformation. Research Studies Press, Wiley, New York, N.Y.
7. De Clercq, E. 2001. Antiviral drugs: current state of the art. J. Clin. Virol. 22:73-89.
8. De Francesco, R., and C. M. Rice. 2003. New therapies on the horizon for hepatitis C: are we close? Clin. Liver Dis. 7:211-242.
9. Desgranges, C., E. De Clercq, G. Razaka, F. Drouillet, I. Belloc, and H. Bricaud. 1986. Deoxyribosyl exchange reactions leading to the in vivo generation and regeneration of the antiviral agents (E)-5-(2-bromovinyl)-2′- deoxyuridine, 5-ethyl-2′-deoxyuridine and 5-(2-chloroethyl)-2′- deoxyuridine. Biochem. Pharmacol. 35:1647-1653.
10. Eldrup, A. B., C. R. Allerson, C. F. Bennett, S. Bera, B. Bhat, M. R. Bosserman, J. Brooks, C. Burlein, S. S. Carroll, P. D. Cook, K. L. Getty, M. MacCoss, D. R. MacMasters, D. B. Olsen, T. Prakash, M. Prhave, Q. Song, J. E. Tomassini, and J. Xia. 2004. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47:2283-2295.
11. Gu, B., V. K. Johnston, L. L. Gutshall, T. T. Nguyen, R. R. Gontarek, M. G. Darcy, R. Tedesco, D. Dhanak, K. J. Duffy, C. C. Kao, and R. T. Sarisky. 2003. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J. Biol. Chem. 278:16602-16607.
12. Guo, J. T., V. V. Bichko, and C. Seeger. 2001. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:8516-8523.
13. Reference deleted.
14. Reference deleted.
15. Krajewska, E., and D. Shugar. 1975. Alkylated cytosine nucleosides: substrate and inhibitor properties in enzymatic deamination. Acta Biochim. Pol. 22:185-194.
16. Kries, W., K. A. Watanabe, and J. J. Fox. 1978. Structural requirements for the enzymatic deamination of cytosine nucleosides. Helv. Chim. Acta 61: 1011-1016.
17. Kuszewski, J., M. Nilges, and A. T. Brunger. 1992. Sampling and efficiency of metric matrix distance geometry: a novel partial metrization algorithm. J. Biomol. NMR 2:33-56.
18. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
19. 18a. Lefebvre, I., C. Périgaud, A. Pompon, A.-M. Aubertin, J.-L. Girardet, A. Kirn, G. Gosselin, and J.-L. Imbach. 1995. Mononucleoside phosphotriester derivatives with S-aceyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′, 3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38:3941-3950.
20. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
21. Love, R. A., H. E. Parge, X. Yu, M. J. Hickey, W. Diehl, J. Gao, H. Wriggers, A. Ekker, L. Wang, J. A. Thomson, P. S. Dragovich, and S. A. Fuhrman. 2003. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77:7575-7581.
22. Maehara, Y., H. Nakamura, Y. Nakane, K. Kawai, M. Okamoto, S. Nagayama, T. Shirasaka, and S. Fujii. 1982. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann 73:289-298.
23. Marquez, V. E. 1989. Inhibition of cytidine deaminase: mechanism and effect on the metabolism of antitumor agents, p. 91-114. In R. I. Glazer (ed.), Developments in cancer chemotherapy. CRC Press, Boca Raton, Fla.
24. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. 2003. Characterization of resistance to non-obligate chain terminating ribonucleoside analogs which inhibit HCV replication in vitro. J. Biol. Chem. 278:49164-49170.
25. Mohamadi, F., N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufleld, G. Chang, T. Hendrickson, and W. C. Still. 1990. Macro-Model-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11:4.
26. Mottola, G., G. Cardinali, A. Ceccacci, C. Trozzi, L. Bartholomew, M. R. Torrisi, E. Pedrazzini, S. Bonatti, and G. Migliaccio. 2002. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 293:31-43.
27. Narjes, F., U. Koch, C. Steinkuhler. 2003. Recent developments in the discovery of hepatitis C virus serine protease inhibitors-towards a new class of antiviral agents? Expert Opin. Investig. Drugs 12:153-163.
28. O'Farrell, D., R. Trowbridge, D. Rowlands, and J. Jager. 2003. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol. 326:1025-1035.
29. Pause, A., G. Kukolj, M. Bailey, M. Brault, F. Do, T. Halmos, L. Lagace, R. Maurice, M. Marquis, G. McKercher, C. Pellerin, L. Pilote, D. Thibeault, and D. Lamarre. 2003. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 278:20374-20380.
30. Prakash, T. P., S. S. Carroll, B. Bhat, M. Prhave, D. B. Olsen, A. B. Eldrup, M. MacCoss, J. E. Tomassini, S. M. Galloway, C. H. Hughes, and P. D. Cook. 2005. Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5′-monophosphates as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 48:1199-1210.
31. Shim, J. H., G. Larson, V. Lai, S. Naim, and J. Z. Wu. 2003. Canonical 3′-dexoyribonucleotides as a chain terminator for HCV RNA-dependent RNA polymerase. Antiviral Res. 58:243-251.
32. Stein, D. S., and K. H. P. Moore. 2001. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 21:11-34.
33. Stuyver, L. J., T. R. McBrayer, P. M. Tharnish, A. E. A. Hassan, C. K. Chu, K. W. Pankiewicz, K. A. Watanabe, R. F. Schinazi, and M. J. Otto. 2003. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 77:10689-10694.
34. Tomassini, J. E., E. Boots, L. Gan, P. Graham, V. Munshi, B. Wolanski, J. F. Fay, K. Getty, and R. LaFemina. 2003. An in vitro Flaviviridae replicase system capable of authentic RNA replication. Virology 313:274-285.
35. Tomei, L., S. Altamura, L. Bartholomew, M. Bisbocci, C. Bailey, M. Bosserman, A. Cellucci, E. Forte, I. Incitti, L. Orsatti, U. Koch, R. De Francesco, D. B. Olsen, S. S. Carroll, and G. Migliaccio. 2004. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78:938-946.
36. Tomei, L., S. Altamura, L. Bartholomew, A. Biroccio, A. Ceccacci, L. Pacini, F. Narjes, N. Gennari, M. Bisbocci, I. Incitti, L. Orsatti, S. Harper, I. Stansfleld, M. Rowley, R. De Francesco, and G. Migliaccio. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77:13225-13231.
37. Trozzi, C., L. Bartholomew, A. Ceccacci, G. Biasiol, L. Pacini, S. Altamura, F. Narjes, E. Muraglia, G. Paonessa, U. Koch, R. De Francesco, C. Steinkuhler, and G. Migliaccio. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77:3669-3679.
38. Walker, M. P., N. Yao, and Z. Hong. 2003. Promising candidates for the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs 12:1269-1280.
39. Wang, M., K. K. Ng, M. M. Cherney, L. Chan, C. G. Yannopoulos, J. Bedard, N. Morin, N. Nguyen-Ba, M. H. Alaoui-Ismaili, R. C. Bethell, and M. N. James. 2003. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278:9489-9495.
40. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:1-16.
41. Xiang, S., S. A. Short, R. Wolfenden, and C. W. Carter, Jr. 1996. Cytidine deaminase complexed to 3-deazacytidine: a "valence buffer" in zinc enzyme catalysis. Biochemistry 35:1335-1341.